Detalhe da pesquisa
1.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
Blood
; 118(11): 2970-5, 2011 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21690557